• 1
    Bergner M. Quality of life, health status, and clinical research. Med Care 1989;27(Suppl):S14856.
  • 2
    Patrick DL, Erickson P. Health Status and Health Policy: Allocating Resources to Health Care. New York: Oxford University Press, 1993.
  • 3
    Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999;2: 11327.
  • 4
    Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000;9: 887900.
  • 5
    Santanello NC, Baker D, Cappelleri JC. Regulatory issues for health-related quality of life—PhRMA Health Outcomes Committee Workshop, 1999. Value Health 2002;5: 1425.
  • 6
    Chassany O, Sagnier P, Marquis P, et al. Patient-reported outcomes: the example of health-related quality of life—A European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. DIA J 2002;36: 20938.
  • 7
    Burke L. Acceptable evidence for pharmaceutical advertising and labeling. DIA Workshop on Pharmacoeconomics and Quality of Life Labeling and Marketing Claims. 2000 Oct 3; New Orleans (LA). Horsham (PA): Drug Information Association; 2000.
  • 8
    Rothman ML, Hedrick SC, Bulcroft KA, et al. Effects of adult day health care on health outcomes and satisfaction with care. Med Care 1993;31: 3849.
  • 9
    Rothman M, Farup C, Stewart W, et al. Symptoms associated with gastroesophageal reflux disease: development of a questionnaire for use in clinical trials. Dig Dis Sci, 2001;46: 154048.
  • 10
    Portenoy RK, Thaler HT, Kornblith AB, et al. The memorial symptom assessment scale. an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 1994; 30A: 132636.
  • 11
    Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes. JAMA 1995;273: 5965.
  • 12
    American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152(Suppl):S77120.
  • 13
    National  Heart,  Lung  and  Blood  Institute  & World Health Organization. Global Initiative for Chronic Obstructive Lung Disease [Internet]. Publication No. 2701A. Bethesda (MD): US Department of Health and Human Services, Public Health Service, National Institutes of Health; 2001. Available from:
  • 14
    Eltayara L, Becklace MR, Volta CA, et al. Relationship between chronic dyspnea and expiratory flow limitation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;154(6 Pt 1):172634.
  • 15
    Hajiro T, Nishimura K, Tsukino M, et al. Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157(3 Pt 1):78590.
  • 16
    O-Donnell DE. Assessment of bronchodilator efficacy in symptomatic COPD: is spirometry useful? Chest 2000;117: S427.
  • 17
    Bostrom C. Shoulder rotational strength, movement, pain and joint tenderness as indicators of upper-extremity activity limitation in moderate rheumatoid arthritis. Scand J Rehab Med 2000; 32: 1349.
  • 18
    Lee CE, Simmonds MJ, Novy DM, et al. Self-reports and clinician-measured physical function among patients with low back pain: a comparison. Arch Phys Med Rehabil 2001;82: 22731.
  • 19
    Kaliner M. Allergy care in the next millennium: guidelines for the specialty. Presidential Address. J Allergy Clin Immunol 1997;99: 72934.
  • 20
    An evidence-based appraisal of reflux disease management—Genval Workshop Report. Gut 1999; 44(Suppl 2):S116.
  • 21
    Boers M, Brooks P, Strand V, et al. The OMERACT filter for outcome measures in rheumatology. J Rheumatol 1998;25: 1989.
  • 22
    Strand V, Gladman D, Isenber D, et al. Endpoints: consensus recommendations from OMERACT IV. Lupus 2000;9: 3227.
  • 23
    Cramer JA, Arrigo C, Van Hammee G, et al. The effect of levetiracetam on epilepsy-related quality of life. Epilepsia 2000;41: 86874.
  • 24
    Santanello NC, Polis AB, Hartmaier SL, et al. Improvement in migraine-specific quality of life in a clinical trial of rizatriptan. Cephalalgia 1997; 17: 86772.
  • 25
    Group for the Respect of Ethics and Excellence in Science (GREES) Rheumatoid Arthritis Section. Recommendations for the registration of drugs used  in  the  treatment  of  rheumatoid  arthritis. Br J Rheumatol 1998;37: 2115.
  • 26
    Johnson JR, Temple R. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep 1985;69: 1559.
  • 27
    Lohr KN, Aaronson NK, Alonso J, et al. Evaluating quality-of-life and health status instruments: development of scientific review criteria. Clin Ther 1996;18: 97992.
  • 28
    Von Neumann J, Morgenstern O. Theory of Games and Economic Behavior. Princeton: Princeton University Press, 1944.
  • 29
    Likert R. A technique for the measurement of attitudes. Arch Psychol 1932;140: 155.
  • 30
    Cronbach L, Meehl P. Construct validity in psychological tests. Psychol Bull 1955: 281302.
  • 31
    Nunnally J, Bernstein I. Psychometric Theory (3rd ed.). New York: McGraw-Hill, 1994.
  • 32
    Hays R, Anderson R, Revicki DA. Assessing reliability and validity of measurement in clinical trials. In: StaquetMJ, HaysRD, FayersPM, eds. Quality of Life Assessment in Clinical Trials. New York: Oxford University Press, 1998.
  • 33
    Fayers PM, Hopwood P, Harvey A, et al. Quality of life assessment in clinical trials—guidelines and a checklist for protocol writers: the UK medical research council experience. Eur J Cancer 1997; 33: 208.
  • 34
    Machin D, Weeden S. Suggestions for presentation of quality of life data from clinical trials. Stat Med 1998;17: 71124.
  • 35
    Sanders C, Egger M, Donovan J, et al. Reporting on quality of life in randomised controlled trials: bibliographic study. Br Med J 1998;317: 11914.
  • 36
    Prevalence of disability and associated health conditions—United States, 1991–1992. Morb Mortal Wkly Rep 1994;43: 7301,737–9.
  • 37
    CDC  Chronic  Disease  Prevention.The  Burden of Chronic Diseases and Their Risk Factor—National and State Perspectives. Washington: U.S. Department of Health and Human Services, 2002.
  • 38
    Segal L. The importance of patient empowerment in health system reform. Health Policy 1998; 44: 3144.
  • 39
    Eysenbach G, Diepgen TL. The role of e-health and consumer health informatics for evidence-based patient choice in the 21st century. Clin Dermatol 2001;19: 117.
  • 40
    Ball MJ, Lillis J. E-health: transforming the physician/patient relationship. Int J Med Inf 2001;61: 110.
  • 41
    Coile RC Jr. The digital transformation of health care. Physician Exec 2000;26: 815.
  • 42
    Coile RC Jr. E-health: reinventing healthcare in the information age. J Healthc Manag 2000;45: 20610.
  • 43
    U.S. Census Bureau. Population Projections of the United States by Age, Sex, Race, Hispanic Origin, and Nativity: 1999 to 2100 [Internet]. Washington: The Bureau, 2000 Feb 14.
  • 44
    Kiebert GM, De Haes JCJM, Van De Velde CJH. The impact of breast-conserving treatment and mastectomy on the quality of life of early-stage breast cancer patients: a review. J Clin Oncol 1991;9: 105970.
  • 45
    Cramer JA. Quality of life assessment for people with epilepsy. In: SpilkerB, ed. Quality of Life and Pharmacoeconomics in Clinical Trials (2nd ed.). Philadelphia: Lippincott-Raven, 1996.
  • 46
    Arunkumar G, Wyllie E, Kotagal P, et al. Parent- and patient-validated content of pediatric epilepsy quality-of-life assessment. Epilepsia 2000; 41: 147484.